Comment on

• Risk of venous thrombosis with hormone-replacement therapy.

  Vandenbroucke JP, Helmerhorst FM. Vandenbroucke JP, et al. Lancet. 1996 Oct 12;348(9033):972. doi: 10.1016/S0140-6736(05)64918-5. Lancet. 1996. PMID: 8855846 No abstract available.
• Risk of venous thromboembolism in users of hormone replacement therapy.

  Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Daly E, et al. Lancet. 1996 Oct 12;348(9033):977-80. doi: 10.1016/S0140-6736(96)07113-9. Lancet. 1996. PMID: 8855852
• Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.

  Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Jick H, et al. Lancet. 1996 Oct 12;348(9033):981-3. doi: 10.1016/S0140-6736(96)07114-0. Lancet. 1996. PMID: 8855853
• Prospective study of exogenous hormones and risk of pulmonary embolism in women.

  Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Grodstein F, et al. Lancet. 1996 Oct 12;348(9033):983-7. doi: 10.1016/S0140-6736(96)07308-4. Lancet. 1996. PMID: 8855854
• Case-control study of venous thromboembolism risk in users of hormone replacement therapy.

  Daly E, Vessey MP, Painter R, Hawkins MM. Daly E, et al. Lancet. 1996 Oct 12;348(9033):1027. doi: 10.1016/S0140-6736(96)24041-3. Lancet. 1996. PMID: 8855869 No abstract available.